Regulatory Review of Method Validation Protocols

Publication
Article
LCGC North AmericaJune 2000
Volume 18
Issue 06
Pages: 620–625

This month's "Validation Viewpoint" column examines the reasons behind problems with new drug applications submitted to the U.S. Food and Drug Administration (FDA). Ira Krull and Michael Swartz look at specific problems within analytical methods that raise red flags at the FDA.

LCGC 18(6), 620–625 (2000).
Related Content